ANCA-associated vasculitis with renal involvement
- 1.3k Downloads
Systemic vasculitis is a rare but severe group of diseases characterized by inflammation and necrosis of blood vessels. The size of the vessel affected varies among the different forms of vasculitis and there are three main subgroups: large, medium and small vessel vasculitis. Among small vessel vasculitis, the antineutrophil cytoplasmic antibody (ANCA)-associated forms are of particular importance. This subgroup includes: microscopic polyangiitis, granulomatosis with polyangiitis (Wegener’s), eosinophilic granulomatosis with polyangiitis (Churg–Strauss) and the form limited to the kidney. ANCA are serum autoantibodies directed against proteins present in the cytoplasmic granules of neutrophils and represent the serological markers of small vessel vasculitis. Renal involvement is present in the majority of patients with ANCA-associated vasculitis (AAV) and the consequences of a missed or delayed diagnosis of renal vasculitis are potentially life threatening. Patient survival and the risk of end-stage renal disease are closely associated with renal function at presentation. The gold standard for diagnosis remains renal biopsy. In 2010, a new histopathological classification based on the percent of normal glomeruli, cellular crescent or global sclerotic glomeruli was proposed. The aim of this classification was to predict the renal prognosis. Nowadays, remission can be achieved and maintained in most cases with a combination of high-dose steroid and immunosuppressive drugs. This therapy has to be continued for at least 24 months after a substantial remission has been obtained because early cessation of treatment is associated with an increased risk of relapse. For this reason, patients should be regularly monitored in order to promptly diagnose and treat a possible recurrence of AAV. This review will focus on kidney involvement in AAV with an overview of the clinical–pathological characteristics and therapeutic strategy for these conditions.
KeywordsVasculitis ANCA Pathology Therapy
We would like to thank Andrea Centa and Marina Balderacchi for their secretarial assistance.
Compliance with ethical standards
Conflict of interest
We declare no conflicts of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 5.Watts RA et al (2015) Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant 30(Suppl 1):14–22Google Scholar
- 25.Schirmer JH et al (2016) Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener’s) is a clinically distinct subset of ANCA-associated vasculitis: a retrospective analysis of 315 patients from a German Vasculitis Referral Center. Arthr Rheumatol 68(12):2953–2963CrossRefGoogle Scholar
- 33.Jennette JC, Olson JL, Schwartz MM, Silva FG (eds) (1998) Heptinstall’s pathology of the kidney, 5th edn. Lippincott-Raven publishers, Philadelphia, pp 625–656Google Scholar
- 43.Muso E et al (2013) Evaluation of the newly proposed simplified histological classification in Japanese cohorts of myeloperoxidase-anti-neutrophil cytoplasmic antibody associated glomerulonephritis in comparison with other Asian and European cohorts. Clin Exp Nephrol 17(5):659–662CrossRefPubMedGoogle Scholar
- 44.Moroni G et al (2015) Predictors of renal survival in ANCA-associated vasculitis. Validation of a histopathological classification schema and review of the literature. Clin Exp Rheumatol 33(2 Suppl 89):S56–S63Google Scholar
- 67.Westman K, Flossmann O, Gregorini G (2015) The long-term outcomes of systemic vasculitis. Nephrol Dial Transplant 30(Suppl 1):60–66Google Scholar